Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $41.44 Consensus PT from Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten analysts that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $41.44.

ARWR has been the topic of several research reports. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley reaffirmed a "buy" rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Chardan Capital reissued a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th.

Remove Ads

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 27,167 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.83, for a total transaction of $538,721.61. Following the sale, the chief financial officer now owns 473,433 shares in the company, valued at $9,388,176.39. This trade represents a 5.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the sale, the chief executive officer now owns 3,764,252 shares of the company's stock, valued at $71,709,000.60. The trade was a 0.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 286,317 shares of company stock valued at $5,049,735. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ARWR. Avoro Capital Advisors LLC grew its stake in shares of Arrowhead Pharmaceuticals by 25.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock worth $208,889,000 after purchasing an additional 2,222,223 shares during the last quarter. State Street Corp grew its position in shares of Arrowhead Pharmaceuticals by 8.8% in the 3rd quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company's stock worth $123,083,000 after buying an additional 516,569 shares during the last quarter. Slate Path Capital LP increased its stake in shares of Arrowhead Pharmaceuticals by 7.1% during the fourth quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock valued at $98,362,000 after buying an additional 347,000 shares during the period. Geode Capital Management LLC increased its stake in shares of Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company's stock valued at $57,426,000 after buying an additional 26,171 shares during the period. Finally, Norges Bank bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $38,622,000. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Stock Up 0.1 %

Shares of NASDAQ:ARWR traded up $0.02 during mid-day trading on Thursday, reaching $13.82. 974,317 shares of the stock were exchanged, compared to its average volume of 1,338,889. The stock's 50 day simple moving average is $18.13 and its 200-day simple moving average is $19.61. Arrowhead Pharmaceuticals has a one year low of $13.66 and a one year high of $30.41. The company has a market cap of $1.90 billion, a P/E ratio of -2.67 and a beta of 0.92. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.97). As a group, equities research analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.